Bone Biologics Achieves 29-Month Validated Shelf Life for rhNELL-1
Globe Newswire (Tue, 19-May 8:00 AM ET)
Market Chameleon (Tue, 23-Dec 5:30 AM ET)
Bone Biologics Corp a medical device company that is currently focused on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1. NELL-1 in combination with DBM, demineralized bone matrix, is an osteopromotive recombinant protein that provides target specific control over bone regeneration. It is a clinical-stage entity. The production and marketing of its products and ongoing research and development activities are subject to extensive regulation by numerous governmental authorities in the United States.
Bone Biologics trades on the NASDAQ stock market under the symbol BBLG.
As of June 22, 2026, BBLG stock price declined to $1.37 with 44,467 million shares trading.
BBLG has a beta of 0.97, meaning it tends to be less sensitive to market movements. BBLG has a correlation of 0.02 to the broad based SPY ETF.
BBLG has a market cap of $2.46 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, BBLG traded as high as $725.76 and as low as $1.05.
BBLG has underperformed the market in the last year with a return of -74.2%, while SPY returned +26.5%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in BBLG shares. However, BBLG has outperformed the market in the last 3 month and 2 week periods, returning +13.2% and +9.6%, while SPY returned +13.1% and -1.4%, respectively. This indicates BBLG has been having a stronger performance recently.
BBLG support price is $1.38 and resistance is $1.54 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BBLG shares will trade within this expected range on the day.
